Diagnosis and Management of Anabolic Androgenic Steroid Use
- PMID: 30753550
- PMCID: PMC6517163
- DOI: 10.1210/jc.2018-01882
Diagnosis and Management of Anabolic Androgenic Steroid Use
Abstract
Context: The lifetime prevalence of anabolic androgenic steroid (AAS) use is estimated at 1% to 5% worldwide. AAS use occurs primarily male elite athletes and men who want a muscular appearance. The evidence for effective, safe management of AAS cessation and withdrawal is weak.
Design: Key studies were extracted from PubMed (1990-2018) and Google Scholar with reference searches from relevant retrieved articles.
Results: The proven adverse effects of AASs include suppression of the gonadal axis and infertility, hirsutism and defeminization in women, and erythrocytosis. Alkylated AASs that are taken orally may cause hepatopathy. There is an association between high-dosage AAS use and increased risk of cardiovascular disease. Clues for AAS use include very low serum high-density cholesterol and sex hormone-binding globulin concentrations and unexplained erythrocytosis. For elite athletes, the biological passport (monitoring of blood or urinary androgen and androgen precursor concentrations after determining the athlete's baseline) is useful for detecting AAS use. For nonelite athletes, the best method to confirm AAS use is to inquire in a nonjudgmental manner. Cessation of chronic AAS use is associated with a withdrawal syndrome of anxiety and depression.
Conclusions: Men who use AASs <1 year typically recover normal hypothalamic-pituitary-testicular axis function within 1 year after cessation. Men who have infertility due to high-dosage AAS use ≥1 year might benefit from short-term treatment with clomiphene or human chorionic gonadotropin.
Copyright © 2019 Endocrine Society.
Figures


Comment in
-
Re: Diagnosis and Management of Anabolic Androgenic Steroid Use.J Urol. 2020 Feb;203(2):239. doi: 10.1097/01.JU.0000614760.48465.df. Epub 2019 Nov 11. J Urol. 2020. PMID: 31710536 No abstract available.
Similar articles
-
Advantages and Limitations of Androgen Receptor-Based Methods for Detecting Anabolic Androgenic Steroid Abuse as Performance Enhancing Drugs.PLoS One. 2016 Mar 21;11(3):e0151860. doi: 10.1371/journal.pone.0151860. eCollection 2016. PLoS One. 2016. PMID: 26998755 Free PMC article.
-
MECHANISMS IN ENDOCRINOLOGY: Medical consequences of doping with anabolic androgenic steroids: effects on reproductive functions.Eur J Endocrinol. 2015 Aug;173(2):R47-58. doi: 10.1530/EJE-15-0080. Epub 2015 Mar 24. Eur J Endocrinol. 2015. PMID: 25805894 Review.
-
Studies of athlete biological passport biomarkers and clinical parameters in male and female users of anabolic androgenic steroids and other doping agents.Drug Test Anal. 2020 Apr;12(4):514-523. doi: 10.1002/dta.2763. Epub 2020 Jan 29. Drug Test Anal. 2020. PMID: 31925932
-
The Changing Drug Culture: Use and Misuse of Appearance- and Performance-Enhancing Drugs.FP Essent. 2016 Feb;441:30-43. FP Essent. 2016. PMID: 26881771 Review.
-
Psychological and physical impact of anabolic-androgenic steroid dependence.Pharmacotherapy. 2012 Oct;32(10):910-9. doi: 10.1002/j.1875-9114.2012.01123. Pharmacotherapy. 2012. PMID: 23033230
Cited by
-
Impacts of Anabolic-androgenic steroid supplementation on female health and offspring: Mechanisms, side effects, and medical perspectives.Saudi Pharm J. 2024 Dec;32(12):102205. doi: 10.1016/j.jsps.2024.102205. Epub 2024 Nov 22. Saudi Pharm J. 2024. PMID: 39697477 Free PMC article. Review.
-
Harm Reduction in Male Patients Actively Using Anabolic Androgenic Steroids (AAS) and Performance-Enhancing Drugs (PEDs): a Review.J Gen Intern Med. 2021 Jul;36(7):2055-2064. doi: 10.1007/s11606-021-06751-3. Epub 2021 May 4. J Gen Intern Med. 2021. PMID: 33948794 Free PMC article. Review.
-
Prolonged post-androgen abuse hypogonadism: potential mechanisms and a proposed standardized diagnosis.Front Endocrinol (Lausanne). 2025 Jul 3;16:1621558. doi: 10.3389/fendo.2025.1621558. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40678315 Free PMC article. Review.
-
Current National and International Guidelines for the Management of Male Hypogonadism: Helping Clinicians to Navigate Variation in Diagnostic Criteria and Treatment Recommendations.Endocrinol Metab (Seoul). 2020 Sep;35(3):526-540. doi: 10.3803/EnM.2020.760. Epub 2020 Sep 22. Endocrinol Metab (Seoul). 2020. PMID: 32981295 Free PMC article. Review.
-
Male Fertility After Androgenic Steroid Use: How Little We Know.J Clin Endocrinol Metab. 2021 Jun 16;106(7):e2813-e2815. doi: 10.1210/clinem/dgab236. J Clin Endocrinol Metab. 2021. PMID: 33861859 Free PMC article. No abstract available.
References
-
- Cussons AJ, Bhagat CI, Fletcher SJ, Walsh JP. Brown-Séquard revisited: a lesson from history on the placebo effect of androgen treatment. Med J Aust. 2002;177(11-12):678–679. - PubMed
-
- Kanayama G, Pope HG Jr. History and epidemiology of anabolic androgens in athletes and non-athletes. Mol Cell Endocrinol. 2018;464:4–13. - PubMed
-
- Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med. 1996;335(1):1–7. - PubMed
-
- de Hon O, Kuipers H, van Bottenburg M. Prevalence of doping use in elite sports: a review of numbers and methods. Sports Med. 2015;45(1):57–69. - PubMed